Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Cell Matters logo — Enhancing cell therapy productivity with advanced cryopreser...

Cell Matters

Enhancing cell therapy productivity with advanced cryopreservation solutions and GMP-compliant services.

Founded 2017 Series A Total: $1.01M Biotechnology, Health and Wellness

General Information

Company Name Cell Matters
Founded Year 2017
Industries Biotechnology, Health and Wellness
Funding Stage Series A
Social

Get notified when Cell Matters moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Cell Matters

Cell Matters, founded in 2017, is revolutionizing cell therapy productivity with advanced cryopreservation solutions and GMP-compliant services. The company's slogan, "Enhancing cell therapy productivity with advanced cryopreservation solutions and GMP-compliant services," encapsulates its core mission. By offering an integrated set of GMP services, Cell Matters is ensuring its alignment with the regulatory, quality, and GMP requirements of the cell therapy industry within the biotechnology sector. In January 2018, the company secured a significant €712.00K Series A investment, with key investors including Gesval, Spinventure, and Jean-Pierre Delwart. This capital injection signifies a strong investor confidence in Cell Matters' innovative approach and its potential to make a lasting impact in the field of biotechnology.

Taxonomy: cell therapy, cryopreservation, GMP services, regulatory compliance, quality standards, cell preservation, cellular therapy, biopharmaceuticals

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 3
Investor
•••• •••• 		23 Jan 2018
Grant •••••• 2
Investor
•••• •••• 		23 Jan 2018

Cell Matters Alternatives & Competitors

Cell Matters vs
BioInno
BioInno

Empowering global biopharma with world-class cell culture and GMP production services.

Series A
Biopharma, Biotechnology
Cell Matters vs
cart medical
cart medical

Advancing immune cell therapy with state-of-the-art technologies in a 2,200 square meter GMP and res...

Series A
Health Care, Information Technology
Cell Matters vs
Emmecell
Emmecell United States

Magnetic Cell Delivery Platform for Cell Therapy

11 employees
Biotechnology, Health Care

FAQ About Cell Matters

Enhancing cell therapy productivity with advanced cryopreservation solutions and GMP-compliant services.
Cell Matters was founded in 2017.
Cell Matters operates in the following industries: Biotechnology, Health and Wellness.
Cell Matters has completed 2 funding rounds, raising a total of $1.01M. The latest funding stage is Series A.
Top alternatives and competitors to Cell Matters include BioInno, cart medical, Emmecell, Cell-Easy, Histocell. Regenerative Medicine. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cell Matters and BioInno are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Cell Matters and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy